Neuravi has announced commercial availability of the company’s EmboTrap Revascularisation Device for the treatment of acute ischaemic stroke in Europe. The device will be marketed through the sales and distribution network the company has established in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Spain, Sweden and Switzerland.
Codman Neuro has developed a new MRI-resistant programmable valve with eight different pressure settings, including a ‘virtual off’ setting, for the treatment of hydrocephalus. The announcement was made here at the Seventh Meeting of the International Society for Hydrocephalus and CSF Disorders. Codman Neuro is a global leader in neurosurgery and part of DePuy Synthes Companies of Johnson & Johnson.
Robert Levy, director of the Marcus Neuroscience Institute (MNI) at Boca Raton Regional Hospital, USA, is the first physician in the state of Florida to use the Senza spinal cord stimulation (SCS) system as a method to treat patients with chronic back and leg pain. The Senza SCS system, developed by Nevro, is a spinal cord stimulator that has demonstrated superior results as compared to standard stimulation systems, with patients achieving approximately a 50% greater improvement in pain score than those with traditional SCS therapy.
Medtronic plc has announced that it has acquired Medina Medical, a Menlo Park, California, USA-based and privately-held medical device company focused on commercialising state-of-the-art treatments for vascular abnormalities of the brain including cerebral aneurysms.
Stryker Neurovascular has announced that it has received the CE mark for the Neuroform Atlas Stent System. The Neuroform Atlas Stent is a new 4th-generation adjunctive stent, pushing forward the adjunctive stent landscape which previously included woven, closed-cell, and open-celled stents. According to Stryker Neurovascular, the Neuroform Atlas Stent features an innovative adaptive cell architecture that is designed to optimise conformability and stability when treating wide-neck intracranial aneurysms. Physicians can deliver all sizes of the Neuroform Atlas Stent, from 3.0mm up to 4.5mm in diameter, through a low-profile Excelsior SL-10 microcatheter.
In a 10-site European study reported in the American Journal of Neuroradiology, the safety and efficiency of the single-layer Woven EndoBridge (WEB-SL) device was found to be comparable to that of the older double-layer device. According to the authors, this study is the largest WEB study undertaken to date where WEB-SL devices were used to treat aneurysms that would normally be considered difficult to treat with traditional endovascular approaches.
In a multicentre study, the Aperio thrombectomy device (Acandis) demonstrated safety and efficacy as a tool for reopening occluded cerebral arteries in the setting of an acute ischaemic stroke.
Doctors at Univehe brain of a 71-year-old female patient. Doctors at University Hospital La Timone, Marseille, France, have used their new Leksell Gamma Knife Icon system to treat a metastasis in the brain of a 71-year-old female patient.
During a stroke, slightly more than half of patients use emergency medical services to get to the hospital, with white women the most likely, and Hispanic men the least likely to use emergency transport, according to new research in Journal of the American Heart Association.
Elekta’s Leksell Gamma Knife Icon radiosurgery system has received 510(k) clearance from the US Food and Drug Administration, enabling US healthcare providers to offer this advanced technology to their patients. With stereotactic imaging, online Adaptive DoseControl, ultra-precise dose delivery and the availability of frameless treatments, Icon is capable of treating virtually any target in the brain, regardless of type, location or volume.
A study released at the Society of NeuroInterventional Surgery 12th Annual Meeting (27–30 July, San Francisco, USA), indicates that strict adherence to two commonly-used tools to weigh the risk of treating unruptured aneurysms may not prevent the majority of morbidity-mortality outcomes associated with ruptured intracranial aneurysms. Thus, the International Study of Unruptured Intracranial Aneurysms (ISUIA) criteria and the PHASES score require additional research to determine their effectiveness.
In the last decade, intra-arterial stroke therapy (in which thrombolytic agents and devices are passed through the arteries directly to the clot site) has gained notable momentum as an effective and safe treatment option for patients. Two new studies released at the Society of NeuroInterventional Surgery 12th Annual Meeting (27–30 July, San Francisco, USA) further reinforce the value and progress of intra-arterial treatment and conclude that the new devices that facilitate this approach are reducing treatment times, improving outcomes and decreasing mortality rates.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, has introduced a new platform of embolic coils for the treatment of brain aneurysms, supported by an enhanced detachment system designed to improve microcatheter stability and provide an optimised detachment zone for coils. The announcement was made at the Society of NeuroInterventional Surgery 12th Annual Meeting (SNIS; 27–30 July, San Francisco, USA).
Use of mechanical thrombectomy on qualifying stroke patients could result in major savings to the healthcare economy in the United Kingdom and other western countries with a similar healthcare structure, according to a new study presented at the Society of NeuroInterventional Surgery 12th Annual Meeting in San Francisco, USA.
Two new studies presented at the Society of NeuroInterventional Surgery 12th Annual Meeting in San Francisco, USA, report that Mobile Stroke Treatment Units (MSTUs) can significantly reduce the time it takes to diagnose and treat patients for stroke, greatly improving survival rates and enhancing a patient’s chance of recovery.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos